.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The SYGMA 1 trial examined whether patients with mild asthma could use budesonide–formoterol only when needed rather than rely on a short-acting beta-agonist alone or daily maintenance budesonide. Across 52 weeks, as-needed budesonide–formoterol reduced severe exacerbations substantially compared with as-needed terbutaline, while using much less inhaled corticosteroid than regular twice-daily budesonide. Symptom control, however, was better with scheduled maintenance budesonide. This distinction is clinically important. The study does not suggest that as-needed combination treatment is automatically superior for every patient; rather, it demonstrates that an anti-inflammatory reliever strategy can reduce exacerbation risk while limiting cumulative steroid exposure in selected patients with mild asthma. The findings help frame the NAPCON discussion around everyday asthma phenotyping and practical treatment decisions. For clinicians, the key considerations remain symptom pattern, previous exacerbations, adherence, inhaler technique and the ability to use the regimen correctly. The trial also illustrates why asthma treatment should address airway inflammation rather than relying on a bronchodilator-only rescue approach. Its results became an important part of the evidence base for modern as-needed ICS–formoterol strategies.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The SYGMA 1 trial examined whether patients with mild asthma could use budesonide–formoterol only when needed rather than rely on a short-acting beta-agonist alone or daily maintenance budesonide. Across 52 weeks, as-needed budesonide–formoterol reduced severe exacerbations substantially compared with as-needed terbutaline, while using much less inhaled corticosteroid than regular twice-daily budesonide. Symptom control, however, was better with scheduled maintenance budesonide. This distinction is clinically important. The study does not suggest that as-needed combination treatment is automatically superior for every patient; rather, it demonstrates that an anti-inflammatory reliever strategy can reduce exacerbation risk while limiting cumulative steroid exposure in selected patients with mild asthma. The findings help frame the NAPCON discussion around everyday asthma phenotyping and practical treatment decisions. For clinicians, the key considerations remain symptom pattern, previous exacerbations, adherence, inhaler technique and the ability to use the regimen correctly. The trial also illustrates why asthma treatment should address airway inflammation rather than relying on a bronchodilator-only rescue approach. Its results became an important part of the evidence base for modern as-needed ICS–formoterol strategies.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
4 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
5 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
5 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
